Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
14.25
-0.48 (-3.26%)
Jan 8, 2025, 4:00 PM EST - Market closed
Company Description
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.
Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
Palvella Therapeutics, Inc.
Country | United States |
Founded | 2015 |
CEO | Wesley Kaupinen |
Contact Details
Address: 125 Strafford Avenue, Suite 360 Wayne, Pennsylvania 19087 United States | |
Phone | 484 253 1461 |
Website | palvellatx.com |
Stock Details
Ticker Symbol | PVLA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001742961 |
Employer ID | 81-2228053 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Wesley Kaupinen | Chief Executive Officer |
Matthew Korenberg | Chief Financial Officer |
Kathleen Goin | Chief Operating Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 30, 2022 | D | Notice of Exempt Offering of Securities |
Jun 3, 2020 | D | Notice of Exempt Offering of Securities |
Aug 12, 2019 | D/A | Filing |
Apr 12, 2019 | D | Notice of Exempt Offering of Securities |
Jun 14, 2018 | D | Notice of Exempt Offering of Securities |